Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Gerresheimer rises after stronger quarterly results and optimistic outlook
Gerresheimer shares climbed by more than three percent after preliminary third-quarter results. Revenue beat market expectations by about six percent, while operating profit largely met expectations. Management said it was optimistic about a stronger final quarter. For the previous year the group reports a loss of almost €319 million due to large write-downs; a return to the SDAX is being discussed again in light of the recovery. » More on finanzen.net
Gerresheimer grows in third quarter despite stagnant adjusted EBITDA
Gerresheimer increased revenue in the third quarter by 8% to €605 million; adjusted EBITDA remained at €103 million, just behind the prior year (€106m). In the first nine months, inventory reduction and weaker businesses in tubular glass Europe and container glass weighed on adjusted EBITDA. The group expects a stronger fourth quarter and is advancing the sale of its primary plastic packaging business (PPP); closing is expected in Q1 2027. » More on wiwo.de
Gerresheimer completes sale of Centor to Apax Partners
Gerresheimer has completed the sale of its US business Centor to Apax Partners; the proceeds are to be used primarily to reduce debt. The separation of the Primary Packaging Plastics division is to take place in the first half of 2027. After the transaction, which is part of a portfolio shift toward primary packaging and drug-delivery systems, the share price fell intraday by up to 3.35 percent. » More on finanzen.net
Gerresheimer increases adjusted EBITDA significantly in second quarter and plans sale of Centor
Gerresheimer reports operational improvements in preliminary Q2 results: revenue €578m (adjusted €614m prior year) and adjusted EBITDA €102m (adjusted €126m prior year). Adjusted EBITDA is more than 50% above the previous quarter, which the CFO says is a sign that the transformation program is taking effect. To reduce debt, the US subsidiary Centor and the primary packaging plastics business are to be sold; deals are expected shortly. Gerresheimer expects to publish final Q2 and H1 figures by the end of November. » More on deraktionaer.de
Gerresheimer shows clear operational recovery in second quarter
In the second quarter, revenue rose quarter-on-quarter by 10.5% to €578 million, adjusted EBITDA climbed by over 50% to €102 million and the operating margin improved to 17.6%. Compared with the previous year, however, revenue and EBITDA remain below the 2025 level, so the half-year result is slightly down. The full-year guidance was lowered to the lower half of the previous revenue range (€2.3–2.4 billion) and to an adjusted EBITDA margin of 17–18%, while the planned sale of Centor and the plastic packaging business to Apax (enterprise value around €1.5 billion) is intended to help reduce debt. If the recovery continues and the targets are met, the company sees significant turnaround potential after the share-price crash. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | February 2026 | YoY |
|---|---|---|
| Revenue | 474.94m | - |
| Gross profit | 49.26m | - |
| Net profit | -98.32m | - |
| EBITDA | 9.56m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.08bn |
Number of shares | 34.54m |
52-week high/low | €34.20 - €14.83 |
| Dividends | No |
Beta | 0.47 |
P/E ratio | -2.69 |
PEG ratio | 0.01 |
P/B ratio | 1.13 |
P/S ratio | 0.47 |
Company profile
Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.
| Name | Gerresheimer |
| CEO | Uwe Ferdinand Röhrhoff |
| Headquarters | Düsseldorf,
nw Germany |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 11/06/2007 |
| Employees | 13,301 |
Ticker symbols
| Exchange | Symbol |
|---|---|
XETRA | GXI.DE |
Pnk | GRRMF |
SIX | GXI.SW |
Frankfurt | GXI.F |
Düsseldorf | GXI.DU |
Hamburg | GXI.HM |
London | 0NTI.L |
München | GXI.MU |
Wien | GXI.VI |